Skip to main content

Drug Interactions between etravirine and Telzir

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

fosamprenavir etravirine

Applies to: Telzir (fosamprenavir) and etravirine

GENERALLY AVOID: Etravirine has been shown to significantly increase the plasma concentrations of amprenavir administered as fosamprenavir/ritonavir. The mechanism of interaction has not been described. In eight study subjects administered fosamprenavir/ritonavir (700 mg/100 mg) twice a day with etravirine, amprenavir peak plasma concentration (Cmax), systemic exposure (AUC) and trough plasma concentration (Cmin) increased by 62%, 69% and 77%, respectively. No data are available for fosamprenavir and etravirine without low-dose ritonavir as a pharmacokinetic booster.

MANAGEMENT: Appropriate dosages for the combination of etravirine and fosamprenavir/ritonavir have not been established. Due to a significant increase in amprenavir systemic exposure, fosamprenavir/ritonavir should not be prescribed in combination with etravirine. Unboosted fosamprenavir (i.e., without low-dose ritonavir) should also not be used with etravirine according to the product labeling for etravirine.

References

  1. (2008) "Product Information. Intelence (etravirine)." Ortho Biotech Inc

Switch to consumer interaction data

Drug and food interactions

Moderate

fosamprenavir food

Applies to: Telzir (fosamprenavir)

ADJUST DOSING INTERVAL: Food may reduce the systemic bioavailability of amprenavir from fosamprenavir oral suspension. The mechanism of interaction has not been described. According to the product labeling, administration of fosamprenavir oral suspension (1400 mg single dose) with a high-fat meal (967 kcal, 67 g fat, 33 g protein, 58 g carbohydrate) reduced amprenavir peak plasma concentration (Cmax) by 46% and systemic exposure (AUC) by 28% compared to administration in a fasted state. The time to reach peak plasma level (Tmax) was delayed by 0.72 hours. In contrast, the same high-fat meal did not affect the pharmacokinetics of amprenavir from fosamprenavir tablets.

MANAGEMENT: Fosamprenavir suspension should be administered on an empty stomach in adults, but with food in pediatric patients to aid palatability and compliance. If emesis occurs within 30 minutes after dosing the suspension, the dose should be repeated. Fosamprenavir tablets may be taken with or without food.

References

  1. (2003) "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline

Switch to consumer interaction data

Moderate

etravirine food

Applies to: etravirine

ADJUST DOSING INTERVAL: Coadministration with food increases the oral bioavailability of etravirine. The mechanism is unknown. Compared to administration following a meal, the systemic exposure (AUC) to etravirine was decreased by about 50% when the drug was administered under fasting conditions. The types of meal studied (ranging from 345 kilocalories containing 17 grams fat to 1160 kilocalories containing 70 grams fat) did not appear to make a difference with respect to impact on etravirine bioavailability.

MANAGEMENT: Etravirine should always be administered following a meal.

References

  1. (2008) "Product Information. Intelence (etravirine)." Ortho Biotech Inc

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer